Studies have shown that MMR deficiency is a better predictor of response to PD-1/PD-L1 inhibitor therapy than tumor grade in EC, and immune PD-L1 expression was observed in 100% of dMMR cases as compared to 66% of MMR-proficient cases [36]. The gene discussed is MRC1; the disease is neoplasm.